Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review

April 2021 | 61 pages | ID: KA0AD0497AAEN
GlobalData

Abstracts

Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Karyopharm Therapeutics Inc (Karyopharm Therapeutic) discovers and develops novel drugs for the treatment of cancer and other diseases. The company develops small molecule selective inhibitors of nuclear export compounds that combat the nuclear export of XPO1 protein. Karyopharm’s lead product include Xpovio developed for treatment of multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma. Its pipeline drug candidates include selinexor, verdinexor, eltanexor, and KPT-9274. Karyopharm drug candidates are indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and endometrial cancer. The company has operations in the US, Israel and Germany. Karyopharm is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc Key Recent Developments

Feb 04,2021: Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 2021
Jan 11,2021: Karyopharm announces preliminary unaudited fourth quarter and full year 2020 total revenues and provides commercial update
Dec 15,2020: Karyopharm appoints Michael Mano as Senior Vice President, General Counsel and reports inducement grants under Nasdaq listing rule 5635(c)(4)
Nov 02,2020: Karyopharm reports third quarter 2020 financial results and highlights recent company progress
Aug 31,2020: Karyopharm Therapeutics appoints Christy J. Oliger to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Karyopharm Therapeutics Inc - Key Facts
Karyopharm Therapeutics Inc - Key Employees
Karyopharm Therapeutics Inc - Key Employee Biographies
Karyopharm Therapeutics Inc - Major Products and Services
Karyopharm Therapeutics Inc - History
Karyopharm Therapeutics Inc - Company Statement
Karyopharm Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Karyopharm Therapeutics Inc - Business Description
Product Category: License and Other Revenue
Performance
Product Category: Product Revenue
Performance
R&D Overview
Karyopharm Therapeutics Inc - Corporate Strategy
Karyopharm Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Karyopharm Therapeutics Inc - Strengths
Karyopharm Therapeutics Inc - Weaknesses
Karyopharm Therapeutics Inc - Opportunities
Karyopharm Therapeutics Inc - Threats
Karyopharm Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Karyopharm Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 04, 2021: Karyopharm to Report Fourth Quarter and Full Year 2020 Financial Results on February 2021
Jan 11, 2021: Karyopharm announces preliminary unaudited fourth quarter and full year 2020 total revenues and provides commercial update
Dec 15, 2020: Karyopharm appoints Michael Mano as Senior Vice President, General Counsel and reports inducement grants under Nasdaq listing rule 5635(c)(4)
Nov 02, 2020: Karyopharm reports third quarter 2020 financial results and highlights recent company progress
Aug 31, 2020: Karyopharm Therapeutics appoints Christy J. Oliger to its Board of Directors
Aug 04, 2020: Karyopharm reports second quarter 2020 financial results and highlights recent company progress
May 05, 2020: Karyopharm reports first quarter 2020 financial results and highlights recent company progress
Mar 12, 2020: Karyopharm expands executive leadership team with the appointment of John Demaree as Chief Commercial Officer
Feb 13, 2020: Karyopharm reports fourth quarter and full year 2019 financial results and highlights recent company progress

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Karyopharm Therapeutics Inc, Key Facts
Karyopharm Therapeutics Inc, Key Employees
Karyopharm Therapeutics Inc, Key Employee Biographies
Karyopharm Therapeutics Inc, Major Products and Services
Karyopharm Therapeutics Inc, History
Karyopharm Therapeutics Inc, Subsidiaries
Karyopharm Therapeutics Inc, Key Competitors
Karyopharm Therapeutics Inc, Ratios based on current share price
Karyopharm Therapeutics Inc, Annual Ratios
Karyopharm Therapeutics Inc, Annual Ratios (Cont...1)
Karyopharm Therapeutics Inc, Interim Ratios
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Karyopharm Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Karyopharm Therapeutics Inc, Performance Chart (2016 - 2020)
Karyopharm Therapeutics Inc, Ratio Charts
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021